Physician profile
Christopher Thaver
NPI 1407334675
$1,260.00
in general payments reported to CMS, 2019-2025
18 companies · $660 in 2025
The $660 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.36 · 2022: $160 · 2023: $287 · 2024: $140 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $253.63 | 2022-2025 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $248.93 | 2025 | Voquezna |
| Lilly USA, LLC | $207.92 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $134.04 | 2023-2025 | Ubrelvy, Qulipta, Vraylar |
| Exact Sciences Corporation | $79.25 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $75.47 | 2022-2023 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $41.26 | 2025 | Breztri, Farxiga |
| Boston Scientific Corporation | $33.77 | 2025 | Watchman Flx |
| Shield Therapeutics INC | $26.52 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.44 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $21.38 | 2025 | |
| Pfizer INC. | $21.15 | 2025 | |
| Amgen INC. | $19.91 | 2025 | Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $17.28 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $16.90 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $13.69 | 2022 | |
| Eisai INC. | $12.36 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Thaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.